MTOR and hepatocellular carcinoma: In HCC patients, activation of the mTOR pathway was observed in 40-50% HCC patients and was closely associated with HCC poor prognosis and early recurrence [17, 20], which facilitated the development of mTOR inhibitors for clinical applications.